Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
AB Sciex
FOCUS DIAGNOSTICS, INC.

Leukocyte Ratio Predicts Ulcerative Colitis Severity

By Labmedica International staff writers
Posted on 11 Feb 2013
Blood neutrophil-to-lymphocyte (N/L) ratio is an indicator of the overall inflammatory status of the body, and an alteration in N/L ratio may be found in ulcerative colitis (UC) patients.

An optimal test has not yet been developed for UC and therefore the adjunctive use of additional blood markers may add a significant advantage for predicting disease severity and achieving diagnostic precision.

Medical scientists at Erciyes University (Kayseri, Turkey) enrolled 26 UC patients, 18 males and 8 females, and 28 healthy controls, 10 males and 18 females in the study. Complete blood counts, erythrocyte sedimentation rates (ESR), and C-reactive protein levels (CRP) were established for both patients and controls. The white blood count (WBC), neutrophil, and lymphocyte counts were recorded, and the N/L ratios were calculated from these parameters. The median disease duration in UC patients was 2.75 years.

The N/L ratios of patients with active UC were significantly higher at 3.85 ± 2.71 than those of inactive UC at 2.40 ± 1.05 and controls at 1.77 ± 0.68 were. The optimum N/L ratio cut-off point for active UC was 2.47. There was no significant difference between inflammation parameters, disease extension, and disease activity. The other inflammation markers such as ESR and CRP were also higher in the patients with active UC.

The authors concluded that in patients with UC, the N/L ratio is strongly associated with active disease. Unlike many other noninvasive markers of UC, the N/L ratio is inexpensive and readily available. Although the accuracy of the N/L ratio for detecting active UC is suboptimal, the ratio is an easily derived measure that might, in combination with other markers, assist in identifying patients at increased risk of active and severe disease. The study was published in the January 2013 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

Erciyes University



77 ELEKTRONIKA
PURITAN MEDICAL
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.